Heron Therapeutics vs Niagen Bioscience
Heron Therapeutics is the larger business, with $155m of revenue in fiscal 2025 against $129m for Niagen Bioscience (1.2 times as much). Niagen Bioscience grew faster (29.9% against 7.4%). Niagen Bioscience kept more of each dollar of sales as profit: a net margin of 13.4% against -13.0%.
| Latest fiscal year | Heron TherapeuticsHRTX, 2025 | Niagen BioscienceNAGE, 2025 |
|---|---|---|
| Revenue | $155m | $129m |
| Revenue growth | 7.4% | 29.9% |
| Net income | −$20.2m | $17.4m |
| Operating margin | -1.6% | — |
| Net margin | -13.0% | 13.4% |
| Return on equity | — | 28.3% |
| Free cash flow | −$27.9m | $13.5m |
| Cash | $28.6m | $64.8m |
| Total debt | $32.7m | $0 |
| Debt to equity | 228.4% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $251,000 |
| Employees | 128 | — |
| Market value | $52.7m | $185m |
| Price vs our value range | — | Within our value range |
| Moat score | 17 (Weak) | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 0 sales |